M2N to sell 52% stake in Chinese automotive parts company DKCA
The parent company of Sillajen will use the proceeds to finance future M&A deals
By Dec 28, 2022 (Gmt+09:00)
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![M2N to sell 52% stake in Chinese automotive parts company DKCA](https://www.kedglobal.com/data/ked/image/2022/12/28/ked202212280002.700x.null.png)
M2N( DK D&I Co. ), the parent company of pharmaceutical firm Sillajen Inc., announced on Tuesday that it has signed an agreement to sell its majority stake in its Chinese subsidiary DKC Autotomoitve (DKCA) to a Chinese electric vehicle (EV) parts maker based in Nanchang, Jiangxi Province.
DKCA, established in Jiangsu Province in 2003, is a manufacturer of diesel heaters for diesel filters, sensors, and solenoid valves for engine and powertrain applications.
M2N will dispose of 51.59% of its 70.59% stake in DKCA for about 5 billion won ($3.9 million) and retain the remaining 19%, becoming the second largest shareholder.
M2N's decision to sell its stake is to secure liquidity to finance expansion and build partnerships in the EV market in China.
Currently, it is reviewing several M&A deals to secure an additional growth engine and expects the deals will accelerate with the sale of its DKCA stake.
Seo Hong-min, CEO of M2N, has favored the M&A formula for expansion, including the acquisition of lender The Leadcorp, Inc. in 2008 and SillaJen last year.
Write to Jae-Young Han at jyhan@hankyung.com
-
Bio & PharmaS. Korea's SillaJen launches clinical trials in US for new anti-cancer drug
Dec 14, 2022 (Gmt+09:00)
1 Min read -
Bio & PharmaSillaJen shares jump as exchange maintains listing, allows resumed trade
Oct 13, 2022 (Gmt+09:00)
2 Min read -